RLMD
Relmada Therapeutics, Inc.
$6.21
-0.24 (-3.72%)
At close · Jul 14
Market Cap
$651.37M
Shares
104,890,223
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$13.07K
FY2013
Net Income
-$57.39M
+28.3%
FY2025
Gross Margin
24.75%
FY2013
Operating Margin
-51828.05%
FY2013
Diluted EPS
-$1.45
+45.3%
FY2025
Operating Cash Flow
-$45.79M
+11.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $18.77K | — | — | — | — | — | — | — | — | — | — | — | $13.07K | — | — | — | — | — | — | — | — | |
| — | — | — | $5.15M | $2.66M | $1.2M | $1.4M | $104.11K | -$1.34M | -$550 | $1747 | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $4000 | $14.9K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $14.9K | — | — | — | — | — | — | — | — | — | — | — | $9835 | — | — | — | — | — | — | — | — | |
| $3869 | — | — | — | — | — | — | — | — | — | — | — | $3235 | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | 24.75% | — | — | — | — | — | — | — | — | |
| $23.02M | $26.88M | $46.18M | $54.81M | $113.32M | $90.62M | $35.97M | $7.86M | $2.94M | $1.29M | $6.21M | $7.87M | $5.25M | -$667.47K | — | — | — | — | — | — | — | |
| $37.33M | $32.22M | $37.72M | $48.89M | $47.93M | $35.08M | $24.87M | $7.25M | $3.97M | $5.93M | $10.01M | $9.23M | $1.53M | -$2.49M | — | — | — | — | — | — | — | |
| $60.34M | $59.1M | $83.89M | $103.7M | $161.25M | $125.7M | $60.84M | $15.11M | $6.92M | $7.22M | $16.22M | $17.1M | $6.77M | -$3.16M | — | — | — | — | — | — | — | |
| -$60.34M | -$59.1M | -$83.89M | -$103.7M | -$161.25M | -$125.7M | -$60.84M | -$15.11M | -$6.92M | -$7.22M | -$16.22M | -$17.1M | -$6.77M | -$3.16M | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | -51828.05% | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $4922 | $220.31K | $27.72K | — | — | — | — | — | — | — | |
| $1.92M | $1.4M | $3.53M | $5.15M | — | — | — | — | — | — | — | $10.88K | — | $12.75K | — | — | — | — | — | — | — | |
| $1.47M | $1.72M | $3.91M | $4.91M | $4.21M | -$48.32K | $1.38M | $104.11K | -$2.04M | $932.31K | $13.24M | -$3.7M | -$13.1M | -$3.7M | — | — | — | — | — | — | — | |
| — | — | — | — | -$585.52K | -$636.01K | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$58.88M | -$57.39M | -$79.98M | -$98.79M | -$157.04M | -$125.75M | -$59.46M | -$15.01M | -$8.96M | -$6.29M | -$2.97M | -$20.8M | -$19.87M | -$6.86M | -$873.97K | -$830.93K | -$1.14M | -$1.77M | $217.2K | -$1.03M | -$1.02M | |
| — | — | — | — | — | — | — | — | — | — | — | — | -152042.14% | — | — | — | — | — | — | — | — | |
| USD/shares | — | -$1.45 | -$2.65 | -$3.28 | -$5.30 | -$7.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$1.45 | -$2.65 | -$3.28 | -$5.30 | -$7.16 | — | — | — | — | — | — | -$0.82 | -$0.32 | — | — | — | — | — | — | — |
| shares | — | 39.48M | 30.16M | 30.1M | 29.63M | 17.55M | 15.59M | 9.24M | 12.55M | 12.07M | 11.6M | 9.94M | 485.85K | 2.17M | — | — | — | — | — | — | — |
| shares | — | 39.48M | 30.16M | 30.1M | 29.63M | 17.55M | 15.59M | 9.24M | 12.55M | 12.07M | 11.6M | 9.94M | 24.29M | 21.66M | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.25×
EV/EBIT
—
Biotechnology median 25.44×
P/E (TTM)
—
Biotechnology median 7.40×